Search research articles
Contact Us
Filters
Showing results (351-360 of 429) with videos related to
Page
of 43
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2007
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs
Gregory A Otterson, Miguel A Villalona-Calero, Sunil Sharma, et al.
Eclinicalmedicine
|
July 26, 2021
Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India
Taufik Momin, Kevinkumar Kansagra, Hardik Patel, et al.
Leukemia
|
September 29, 2016
BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells
Dyana T Saenz, Warren Fiskus, Taghi Manshouri, et al.
Journal of Pharmaceutical Sciences
|
April 24, 2013
Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors
Daniele Ouellet, Kenneth F Grossmann, Giselle Limentani, et al.
Targeted Oncology
|
December 2, 2022
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors
Christian Kollmannsberger, Herbert Hurwitz, Lyudmila Bazhenova, et al.
Blood
|
August 9, 2015
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib
Baohua Sun, Bhavin Shah, Warren Fiskus, et al.
Seminars in Oncology
|
October 3, 2003
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group
Chris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Cancer Chemotherapy and Pharmacology
|
September 30, 2016
Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors
John Sarantopoulos, Sanjay Goel, Vincent Chung, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 19, 2021
The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin <i>β</i>-Like 1-<i>β</i>-Catenin Protein Complex
Raffaella Soldi, Tithi Ghosh Halder, Samuel Sampson, et al.
Journal of Clinical Pharmacology
|
August 12, 2017
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis
Neeraj Gupta, Michael J Hanley, Karthik Venkatakrishnan, et al.
Page
of 43
Search research articles
Search
Showing results (351-360 of 429) with videos related to
Sort By:
Page
of 43
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2007
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs
Gregory A Otterson, Miguel A Villalona-Calero, Sunil Sharma, et al.
Eclinicalmedicine
|
July 26, 2021
Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India
Taufik Momin, Kevinkumar Kansagra, Hardik Patel, et al.
Leukemia
|
September 29, 2016
BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells
Dyana T Saenz, Warren Fiskus, Taghi Manshouri, et al.
Journal of Pharmaceutical Sciences
|
April 24, 2013
Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors
Daniele Ouellet, Kenneth F Grossmann, Giselle Limentani, et al.
Targeted Oncology
|
December 2, 2022
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors
Christian Kollmannsberger, Herbert Hurwitz, Lyudmila Bazhenova, et al.
Blood
|
August 9, 2015
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib
Baohua Sun, Bhavin Shah, Warren Fiskus, et al.
Seminars in Oncology
|
October 3, 2003
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group
Chris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Cancer Chemotherapy and Pharmacology
|
September 30, 2016
Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors
John Sarantopoulos, Sanjay Goel, Vincent Chung, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 19, 2021
The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin <i>β</i>-Like 1-<i>β</i>-Catenin Protein Complex
Raffaella Soldi, Tithi Ghosh Halder, Samuel Sampson, et al.
Journal of Clinical Pharmacology
|
August 12, 2017
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis
Neeraj Gupta, Michael J Hanley, Karthik Venkatakrishnan, et al.
Page
of 43